Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIRB 796 BS in moderate to severe plaque-type psoriasis
NCT02209753Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2001
- Primary completion
- Sep 2002
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of doramapimod in plaque psoriasis, sponsored by Boehringer Ingelheim. Started Jun 2001; status: completed.
02
Drugs
doramapimod
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02209753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02209753.